HER2 Breast Cancer Test Market: Introduction

According to the report, the global HER2 breast cancer test market was valued at US$ 313.4 Mn in 2020 and is projected to expand at a CAGR of 6.5% from 2021 to 2031. HER2 stands for human epidermal growth factor receptor 2. It is involved in normal cell growth. Women newly detected with invasive breast cancers should be tested for HER2. The purpose of HER2 testing is to define whether cancer cells have too many copies of the HER2 gene or cancer cells are in developed stage. Cancers with higher-than-normal levels of HER2 are called HER2-positive. Cancers with normal HER2 levels are called HER2-negative.

HER2 status is usually determined using immunohistochemistry (IHC) or fluorescence in situ hybridization (FISH). IHC assesses the expression of the HER2 protein in cell membranes and FISH assesses HER2 gene amplification. Immunohistochemistry (IHC) is the common application of immunostaining. It includes the process of selectively isolating antigens (proteins) in cells of a tissue section by using the principle of antibodies binding specifically to antigens in biological tissues. Fluorescence in situ hybridization (FISH) is a laboratory technique to identify and locate a specific DNA sequence on a chromosome.

Get a sample of the report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=83844

Increase in Incidence Breast Cancer Worldwide

Rise in prevalence of breast cancer across the globe is projected to drive the global HER2 breast cancer test market during the forecast period. Breast cancer in women is a major health burden globally. According to the World Health Organization (WHO), in 2020, there were 2.3 million women diagnosed with breast cancer, with 685,000 deaths globally. As of 2020, there were 7.8 million women alive who were diagnosed with breast cancer in the past five years, making it the world’s most prevalent cancer. Significant disability-adjusted life years (DALYs) are lost by women to breast cancer globally than any other type of cancer.

Breast cancer management can be highly effective, particularly when the disease is identified early. Treatment of breast cancer often consists of a combination of surgical removal, radiation therapy, and medication (hormonal therapy, chemotherapy and/or targeted biological therapy) to treat microscopic cancer that has spread from the breast tumor through the blood. The treatment inhibits cancer growth and spread.

Request for Analysis of COVID-19 Impact on HER2 Breast Cancer Test Market @ https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=83844

Increase in Number of Immunohistochemistry (IHC) Tests

In terms of test type, the global HER2 breast cancer test market has been bifurcated into immunohistochemistry (IHC) and fluorescence/chromogenic in situ hybridization (FISH/CISH). The immunohistochemistry (IHC) segment was valued at US$ 210.6 Mn in 2020 and is projected to reach US$ 413.5 Mn by 2031, expanding at a CAGR of 6.3% from 2021 to 2031. Increase in number of immunohistochemistry (IHC) tests in emerging countries fuels the growth of the segment. Immunohistochemistry (IHC) is used in histology to detect the presence of a specific protein marker that can assist with accurate tumor classification and diagnosis.

Rise in Early Detection Tests Available at Hospitals

In terms of end-user, the global HER2 breast cancer test market has been divided into hospitals and diagnostic laboratories. The hospitals segment accounted for 47.8% share of the market in 2020. The segment is likely to gain market share to reach US$ 523.9 Mn in 2031. Rise in prevalence of breast cancer and early detection tests available in hospitals are projected to propel the global HER2 breast cancer test market during the forecast period.

Increase in the number of cancer treatment hospitals and research institutes across the globe is anticipated to drive the global HER2 breast cancer test market in the near future.

Europe to Lead HER2 Breast Cancer Test Market

The global HER2 breast cancer test market has been segmented into North America, Europe, Latin America, Asia Pacific, and Middle East & Africa. The HER2 breast cancer test market in Europe was valued at US$ 106.1 Mn in 2020 and is expected to reach US$ 207.2 Mn by 2031, expanding at a CAGR of 6.3% from 2021 to 2031.

The HER2 breast cancer test market in Europe is driven by increase in incidence of breast cancer. According to the European Cancer Information System (ECIS), breast cancer was the most common cancer among women in 2018, with incidence of 29.2% of all cancers in the European Union (EU-28).

Make an Enquiry before Buying @ https://www.transparencymarketresearch.com/sample/sample.php?flag=EB&rep_id=83844

Competition Landscape 

The global HER2 breast cancer test market is fragmented due to the presence of a large number of leading players. Key players operating in the global market include Abbott Molecular Inc., Biogenex Laboratories, Inc., Leica Biosystems, Roche, Agilent Technologies, and Mylab, Discovery Solutions Pvt. Ltd.

About Transparency Market Research

Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. The firm scrutinizes factors shaping the dynamics of demand in various markets. The insights and perspectives on the markets evaluate opportunities in various segments. The opportunities in the segments based on source, application, demographics, sales channel, and end-use are analysed, which will determine growth in the markets over the next decade.

Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision-makers, made possible by experienced teams of Analysts, Researchers, and Consultants. The proprietary data sources and various tools & techniques we use always reflect the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in all of its business reports.

For More Research Insights on Leading Industries, Visit Our YouTube Channel and hit subscribe for Future Update - https://www.youtube.com/channel/UC8e-z-g23-TdDMuODiL8BKQ

Contact

Rohit Bhisey
Transparency Market Research Inc.
CORPORATE HEADQUARTER DOWNTOWN,
1000 N. West Street,
Suite 1200, Wilmington, Delaware 19801 USA
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453
Website: https://www.transparencymarketresearch.com
Blog: https://tmrblog.com
Email: sales@transparencymarketresearch.com